RUNX1 isoform imbalance drives ML-DS, VWF-binding RNA aptamer for hemophilia A treatment, and EZH1/2 inhibitor valemetostat in relapsed/refractory ATL
Blood Podcast
00:00
Valametostat 200mg Daily in Patients With Relapse to Refractory ATL
Patients with ATL have few treatment options. Alginia-comatopoietic stem cell transplant can be considered early and up front for aggressive ATL. More than half of transplanted patients fail to achieve long-term survival. Valametostat has received regulatory approval in Japan based on this trial data.
Transcript
Play full episode
